Hydrochlorothiazide + Telmisartan is a fixed-dose combination medication containing Telmisartan, an Angiotensin II Receptor Blocker (ARB), and Hydrochlorothiazide (HCTZ), a thiazide diuretic. It is primarily used to treat essential hypertension (high blood pressure) in patients whose blood pressure is not adequately controlled by either Telmisartan or HCTZ alone. Telmisartan blocks the effect of the hormone angiotensin II to relax blood vessels, while HCTZ works by helping the body eliminate excess salt and water. The combined action provides synergistic blood pressure lowering, reducing the risk of stroke and myocardial infarction (heart attack).

Hydrochlorothiazide + Telmisartan is a combination medicine used to manage high blood pressure (hypertension). It contains two active ingredients: Telmisartan, an angiotensin II receptor blocker (ARB), and Hydrochlorothiazide, a thiazide diuretic. Together, they provide a dual mechanism of action to effectively lower blood pressure and reduce the risk of serious cardiovascular complications such as stroke, heart attack, and kidney damage.

Telmisartan works by blocking the action of angiotensin II, a hormone that causes blood vessels to tighten and narrow. By relaxing and widening the blood vessels, it helps blood flow more easily, lowering pressure on the heart. Whereas, Hydrochlorothiazide increases urine output by helping the kidneys remove excess salt and water from the body. This reduces fluid buildup, decreases blood pressure, and helps prevent swelling.

This combination is particularly useful for patients whose blood pressure is not adequately controlled with a single medication. By targeting blood pressure through two different pathways, Hydrochlorothiazide + Telmisartan offers stronger and more consistent control.

Hydrochlorothiazide + Telmisartan is indicated for:

Treatment of Essential Hypertension:

Primarily used for patients who require combination therapy to achieve target blood pressure goals.

Reduction of Cardiovascular Risk:

By effectively controlling blood pressure, it reduces the long-term risk of developing serious cardiovascular events such as stroke, heart attack, and heart failure.

Superior Antihypertensive Efficacy:

The complementary mechanisms of action of Hydrochlorothiazide + Telmisartan deliver a significant lowering of blood pressure than either single agent can achieve alone. This often allows patients to achieve target blood pressure goals more successfully.

Renal and Cardiovascular Protection:

Effective control of systemic hypertension with Hydrochlorothiazide + Telmisartan is critical for mitigating long-term organ damage, particularly to the kidneys, heart, and vasculature.

Convenience and Adherence:

As a fixed-dose combination, Hydrochlorothiazide + Telmisartan requires taking only one tablet once daily. This reduced pill burden substantially simplifies the treatment regimen, which is clinically proven to improve patient compliance and persistence with therapy.

Favorable Diuretic Dosing:

The inclusion of only 12.5 mg of Hydrochlorothiazide (a generally low diuretic dose) helps maximize the synergistic blood pressure reduction while minimizing the potential for common dose-dependent side effects of diuretics, such as metabolic changes and excessive electrolyte loss.

Hydrochlorothiazide + Telmisartan may cause both common and serious side effects. Most are mild and improve as your body adjusts, but some require medical attention.

Common Side Effects

These are usually mild and may settle with time:

• Dizziness or lightheadedness (especially when standing up quickly)
• Fatigue or weakness
• Headache
• Nausea, diarrhoea, or stomach upset
• Increased urination due to the diuretic effect
• Back pain or muscle cramps
• Mild respiratory symptoms such as cough or throat irritation

Critical Side Effect

Seek medical help immediately if you notice:

• Severe drop in blood pressure (fainting, extreme dizziness)
• Kidney problems (swelling in feet/ankles, reduced urination)
• Electrolyte imbalance (irregular heartbeat, muscle weakness, confusion)
• High potassium levels (palpitations, chest pain)
• Allergic reactions (rash, itching, swelling of face/lips, difficulty breathing)
• Gout attacks due to raised uric acid levels

Always take Hydrochlorothiazide + Telmisartan exactly as prescribed by your doctor.

• Administration: Swallow the tablet whole with a glass of water. It should not be crushed or chewed.
• Timing: The total daily dose is taken once daily at the same time each day.
• Food: The tablet may be taken with or without food.
• Dosing: The typical starting dose is Telmisartan/HCTZ, and the dose is adjusted upward based on the blood pressure response. The dose of 80mg/12.5mg is usually a maintenance or maximum dose for most patients.

Hydrochlorothiazide + Telmisartan lowers blood pressure by combining two medicines that work in different but complementary ways.

• Telmisartan: Telmisartan is a selective angiotensin II receptor antagonist (ARB). It blocks the binding of angiotensin II to AT1 receptors, preventing vasoconstriction and the release of aldosterone. This results in relaxation of vascular smooth muscle, reduced systemic vascular resistance, and improved blood flow. By attenuating the renin–angiotensin–aldosterone system, telmisartan lowers blood pressure and reduces cardiovascular strain.

• Hydrochlorothiazide: Hydrochlorothiazide is a thiazide diuretic that acts on the distal convoluted tubule of the nephron. It inhibits sodium and chloride reabsorption, leading to increased urinary excretion of sodium, chloride, and water. The reduction in plasma volume decreases cardiac output and contributes to blood pressure lowering. Hydrochlorothiazide also promotes mild potassium and magnesium loss while enhancing calcium reabsorption.

• Take once daily, exactly as prescribed, for blood pressure control.
• Regular monitoring of blood pressure, kidney function, and electrolytes is essential.
• Avoid NSAIDs (like ibuprofen) unless advised by your doctor, as they can reduce kidney protection.
• Not safe in pregnancy or breastfeeding, inform your doctor immediately if applicable.
• May increase uric acid and trigger gout in some patients; report joint pain promptly.
• Do not stop the medicine suddenly; always follow medical guidance.

• Store the tablets in their original blister packaging. Telmisartan tablets are highly sensitive to moisture; do not remove them from the blister until immediately before use.
• Store at room temperature, ideally between 20 °C and 25 °C (68 °F and 77 °F).
• Protect from excessive moisture, heat, and direct light.
• Keep the medication out of the reach of children and pets.

• Salt Intake: High salt intake will counteract the blood pressure-lowering effect of both the ARB and the diuretic. A low-salt diet is essential for optimal efficacy.
• Potassium: Avoid high-potassium foods (like bananas, oranges, supplements) in large quantities unless instructed, as Telmisartan can cause hyperkalemia (high potassium), though HCTZ tends to cause hypokalemia (low potassium). The overall effect is variable.

The concurrent use of Hydrochlorothiazide + Telmisartan with certain other agents requires monitoring or should be avoided:

Interactions that Increase Kidney and Electrolyte Risk

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Concomitant administration of NSAIDs (e.g., ibuprofen, diclofenac) significantly elevates the risk of acute renal failure, especially in volume-depleted or elderly patients.

• Potassium-Sparing Diuretics (e.g., Spironolactone, Amiloride): Greatly increase the risk of severe hyperkalemia (high potassium). This combination is generally not recommended.

• Potassium Supplements: Must be strictly avoided unless serum potassium is critically low and monitored.

Interactions Affecting Drug Levels

• Lithium: The combination reduces the clearance of Lithium from the body, leading to potentially toxic serum concentrations. Frequent monitoring of Lithium levels is mandatory.

• Corticosteroids: These can enhance the electrolyte-wasting effect of HCTZ, increasing the likelihood of severe hypokalemia.

Caution is required for patients with:

• Anuria (inability to produce urine) or Severe Renal Impairment: Contraindicated in patients with severe kidney failure.
• Biliary Obstructive Disorders or Severe Hepatic Impairment: Clearance of Telmisartan is reduced.
• Systemic Lupus Erythematosus (SLE): Thiazide diuretics can exacerbate or activate SLE.
• Diabetes Mellitus: HCTZ may affect blood glucose control. Dose adjustments of anti-diabetic medications may be necessary.

The specific strength of Telmisartan 80mg / HCTZ 12.5mg is a high-strength maintenance dose used for patients requiring intensive dual therapy to achieve blood pressure targets.

• Standard Maintenance Dose: One tablet (80mg/12.5mg) once daily.

• Dose Adjustment: Therapy is individualised based on the patient's blood pressure response. The dose is only increased or initiated at this high level after the physician has determined that lower strengths were inadequate.

• Therapeutic Goal: The treatment aims to maintain blood pressure at or below target levels (e.g., 130/80 mmHg) consistently.

An overdose of Hydrochlorothiazide + Telmisartan is most likely to cause profound hypotension (very low blood pressure) and severe electrolyte imbalance (e.g., low potassium, low sodium). Symptoms include severe dizziness, fainting (syncope), rapid heart rate, and signs of dehydration.

If you suspect an overdose, seek immediate emergency medical care. Treatment involves supportive care, including IV fluids to correct dehydration and hypotension, and management of electrolyte disturbances. Telmisartan is not removed by hemodialysis, but HCTZ can be.

If you miss a dose of Hydrochlorothiazide + Telmisartan, take it as soon as you remember. However, if it is already past midday and closer to the time for your next dose (e.g., within 12 hours), skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for the missed one, as this increases the risk of side effects like dizziness and hypotension.